HighGravityDataInsulet — Aug 5, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-26-000167
Showing in the filing
Total Omnipod Revenue Growth - GAAP
“22% - 24%”
Period
FY2026
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 27
Total Revenue Growth - Constant Currency for FY2026
“20% - 22%”
International Omnipod Revenue Growth - Curre… for FY2026
“3%”
U.S. Omnipod Revenue Growth - Constant Curre… for Q3 FY2026
“14% - 16%”
International Omnipod Revenue Growth - Const… for Q3 FY2026
“28% - 30%”
International Omnipod for Q3 FY2026
“28% - 30%”
Total Omnipod Revenue Growth - Constant Curr… for Q3 FY2026
“18% - 20%”
Total Omnipod for Q3 FY2026
“18% - 20%”
Total Omnipod Revenue Growth - Constant Curr… for FY2026
“21% - 23%”
Total Omnipod for FY2026
“21% - 23%”
Drug Delivery Revenue Growth - Constant Curr… for Q3 FY2026
“~(20%)”
Drug Delivery for Q3 FY2026
“~(20%)”
Adjusted Operating Margin for Q3 FY2026
“~100 bps YoY expansion”
Adjusted EPS Growth for Q3 FY2026
“>30%”
Adjusted EPS Growth for FY2026
“>25%”
Total Revenue Growth - GAAP for Q3 FY2026
“17% - 19%”
U.S. Omnipod Revenue Growth - Constant Curre… for FY2026
“17% - 19%”
International Omnipod Revenue Growth - GAAP for FY2026
“33% - 35%”
International Omnipod Revenue Growth - Const… for FY2026
“30% - 32%”
International Omnipod for FY2026
“30% - 32%”
Total Omnipod Revenue Growth - GAAP for FY2026
“22% - 24%”
Total Omnipod Revenue Growth - Currency Impact for FY2026
“1%”
Total Revenue Growth - GAAP for FY2026
“21% - 23%”
International Omnipod Revenue Growth - GAAP for Q3 FY2026
“26% - 28%”
International Omnipod Revenue Growth - Curre… for Q3 FY2026
“(2)%”
Total Omnipod Revenue Growth - GAAP for Q3 FY2026
“17.5% - 19.5%”
Total Revenue Growth - Constant Currency for Q3 FY2026
“17.5% - 19.5%”
Total Omnipod Revenue Growth - Currency Impact for Q3 FY2026
“(0.5)%”
Exhibit 99.1 · the passage around this item
… earlier in the release
10 INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED REVENUE GUIDANCE Year Ending December 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 17% - 19% —% 17% - 19% International Omnipod 33% - 35% 3% 30% - 32% Total Omnipod 22% - 24% 1% 21% - 23% Drug Delivery ~(40%) —% ~(40%) Total 21% - 23% 1% 20% - 22% Three Months Ended September 30, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 14% - 16% —% 14% - 16% International Omnipod 26% - 28% (2)% 28% - 30% Total Omnipod 17.5% - 19.5% (0.5)% 18% - 20% Drug Delivery ~(20%) —% ~(20%) Total 17% - 19% (0.5)% 17.5% - 19.5% 11
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.